EPS for ChromaDex Corporation (CDXC) Expected At $-0.01 on May, 10

April 17, 2018 - By Andrea Pope

ChromaDex Corporation (NASDAQ:CDXC) Corporate Logo

Earnings report for ChromaDex Corporation (NASDAQ:CDXC) is anticipated On May, 10., Faxor reports. Analysts expect change of 80.00 % or $0.04 from previous year’s $-0.05 earnings per share compared to current’s $-0.01 earnings per share. -94.12 % EPS growth is what analysts predict. $-0.17 earnings per share was announced for last [previous quarter]. On during the last trading session the stock increased $0.22 or 5.38%, reaching $4.31.ChromaDex Corporation has volume of 272,755 shares. Since April 17, 2017 CDXC has risen 63.20% and is uptrending. CDXC outperformed by 51.65% the S&P 500.

ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies.The firm is worth $236.34 million. The firm offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside , a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients.Currently it has negative earnings. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications.

ChromaDex Corporation (NASDAQ:CDXC) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.